Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University , Shanghai , China.
J Drug Target. 2014 Jun;22(5):450-9. doi: 10.3109/1061186X.2014.886038. Epub 2014 Feb 11.
To evaluate the internalization and subcellular fate of AS1411 aptamer (for glioma targeting) and TGN peptide (for blood-brain barrier targeting)-modified nanoparticles (AsTNPs), which was important for optimizing targeted delivery systems and realizing the potential toxicity to cells.
Organelles were labelled with specific markers. Several uptake inhibitors were used to determine the endocytosis pathways. Transmission electron microscopy (TEM) was utilized to directly observe the endocytosis procedure and subcellular fate of AsTNPs.
Subcellular localization demonstrated that endosomes and mitochondria were involved in the uptake of AsTNPs by both C6 and bEnd.3 cells, however, lysosomes and Golgi apparatus were only involved in the internalization by C6 cells rather than bEnd.3 cells. Uptake mechanism study demonstrated the clathrin- and caveolae-mediated endocytosis were the main pathways in the uptake of AsTNPs by C6 and bEnd.3 cells. However, other pathways, including clathrin- and caveolae-independent endocytosis and macropinocytosis are also involved in the uptake by C6 cells and not by bEnd.3 cells. TEM directly demonstrated the involvement of these pathways. Particles could be found mostly in endosomes.
Compared to unmodified nanoparticles, AsTNPs displayed different internalization pathways involved in several cell organelles.
评估 AS1411 适体(用于神经胶质瘤靶向)和 TGN 肽(用于血脑屏障靶向)修饰的纳米颗粒(AsTNPs)的内化和亚细胞命运,这对于优化靶向递药系统和实现对细胞的潜在毒性很重要。
用特定的标记物标记细胞器。使用几种摄取抑制剂来确定内吞作用途径。利用透射电子显微镜(TEM)直接观察 AsTNPs 的内吞过程和亚细胞命运。
亚细胞定位表明,内体和线粒体参与了 C6 和 bEnd.3 细胞对 AsTNPs 的摄取,但溶酶体和高尔基体仅参与了 C6 细胞而不是 bEnd.3 细胞的内化。摄取机制研究表明,网格蛋白和小窝介导的内吞作用是 C6 和 bEnd.3 细胞摄取 AsTNPs 的主要途径。然而,其他途径,包括网格蛋白和小窝非依赖性内吞作用和巨胞饮作用也参与了 C6 细胞的摄取,但不参与 bEnd.3 细胞的摄取。TEM 直接证明了这些途径的参与。颗粒主要存在于内体中。
与未修饰的纳米颗粒相比,AsTNPs 显示出不同的内化途径,涉及几种细胞细胞器。